- American City Business Journals•10 days ago
Gaithersburg-based Novavax Inc. canceled its highly anticipated annual investors meeting, opting instead to offer promised data on its recently failed RSV vaccine trial during its third quarter earnings call in November. The delay comes after Novavax (NVAX) revealed Sept. 15 that the so-called Resolve trial that the so-called Resolve trial of the company's candidate to treat RSV — a a respiratory virus that infects the lungs and breathing passages — failed to work as expected in older adults. Erck said the company wants to finalize plans before communicating them during the third-quarter call.
- GlobeNewswire•14 days ago
GAITHERSBURG, Md., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it has rescheduled its 4th annual Investor and Analyst Meeting. The Company will host an Investor and Analyst ...
Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||1.57 x 1000|
|Ask||1.60 x 5000|
|Day's Range||1.56 - 1.62|
|52wk Range||1.16 - 9.23|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.58|
|Avg Vol (3m)||17,278,264|
|Dividend & Yield||N/A (N/A)|